ArticleCancer immunology, immunotherapy : CII2013

Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Haydn Thomas Kissick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.